Literature DB >> 15110804

Intraductal cooling of the main bile ducts during radiofrequency ablation prevents biliary stenosis.

Dominique Elias1, Lucas Sideris, Marc Pocard, Clarisse Dromain, Thierry De Baere.   

Abstract

BACKGROUND: Small-sized tumors sited closer than 15 mm to the central bile ducts cannot be destroyed by radiofrequency (RF) because the resulting heating causes destruction and stenosis of the bile ducts. STUDY
DESIGN: Thirteen patients underwent intraoperative RF to treat tumors closer than 6 mm to a central bile duct. Stenosis prevention was achieved by cooling the main bile duct(s) (right, left, or both) with a 4 degrees C saline solution quickly infused by a catheter introduced inside the bile duct through a choledochotomy. Median followup after cooling was 19.7 months (range 6 to 42 months).
RESULTS: There was no mortality and no RF-related morbidity. Twelve patients (92.3%) did not present any biliary stenosis. In one patient (7.7%) biliary stenosis was detected 6 months after RF. The patient was cirrhotic but did not require any treatment. One of the 13 patients had a local recurrence.
CONCLUSIONS: The intraoperative cooling of central bile ducts prevents biliary stenosis efficiently when using RF to destroy tumors closer than 5 mm to the bile duct. This new technique decreases the contraindications for the use of RF and allows more patients to be treated with RF with curative intent.

Entities:  

Mesh:

Year:  2004        PMID: 15110804     DOI: 10.1016/j.jamcollsurg.2003.12.026

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  15 in total

Review 1.  Complications of intraoperative radiofrequency ablation of liver metastases.

Authors:  Tsiriniaina Razafindratsira; Milène Isambert; Serge Evrard
Journal:  HPB (Oxford)       Date:  2010-12-07       Impact factor: 3.647

2.  Radiofrequency ablation in the liver close to the bile ducts: can intraductal cooling offer protection?

Authors:  U Jersenius; D Arvidsson; J Lindholm; S Anttila; A Elvin
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

3.  Image-guided multipolar radiofrequency ablation of liver tumours: initial clinical results.

Authors:  Sylvain Terraz; Christophe Constantin; Pietro Edoardo Majno; Laurent Spahr; Gilles Mentha; Christoph D Becker
Journal:  Eur Radiol       Date:  2007-03-21       Impact factor: 5.315

4.  Complications of radiofrequency ablation of neoplasms.

Authors:  Albert A Nemcek
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 5.  Complications of image-guided thermal ablation of liver and kidney neoplasms.

Authors:  Kyung Rae Kim; Sarah Thomas
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 6.  A modified surgical approach of hepatopancreatoduodenectomy for advanced gallbladder cancer: Report of two cases and literature review.

Authors:  Jian Wang; Zhan-Guo Zhang; Wan-Guang Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

7.  Radiofrequency ablation as a treatment strategy for liver metastases from breast cancer.

Authors:  Anne M Covey; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2008-12       Impact factor: 1.513

8.  Strategies for resection using portal vein embolization: metastatic liver cancer.

Authors:  Dominique Elias; Diane Goere; Niaz Kohneh-Sahrhi; Thierry de Baere
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

9.  Radiofrequency-assisted versus clamp-crushing parenchyma transection in cirrhotic patients with hepatocellular carcinoma: a randomized clinical trial.

Authors:  Min Li; Wei Zhang; Yi Li; Peizhi Li; Jinzheng Li; Jianping Gong; Yongjun Chen
Journal:  Dig Dis Sci       Date:  2012-09-25       Impact factor: 3.199

10.  Improvised biliary cooling technique for radiofrequency ablation of liver tumours close to central bile ducts.

Authors:  M Elshaer; J White; S S Liau
Journal:  Ann R Coll Surg Engl       Date:  2020-08-24       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.